Group 1 - The core viewpoint of the article highlights that Laibotai Technology has been re-certified as a national-level "specialized and innovative" small giant enterprise, effective for another three years [1] - Laibotai Technology's revenue composition for the year 2024 is detailed, with other sectors accounting for 38.69%, environmental protection at 18.46%, medical testing at 6.91%, disease control at 6.79%, research institutions/universities at 6.61%, food and drug industry at 6.51%, geology/minerals/energy at 5.84%, and third-party testing at 5.6% [1] - The current market capitalization of Laibotai Technology is reported to be 2.4 billion yuan [2]

Core Points - The company, Beijing Leibotai Technology Co., Ltd., has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise for the fourth batch, with a validity period of three years [2] - The company has successfully passed the review and continues to hold the title of national-level "specialized, refined, distinctive, and innovative" small giant enterprise, as announced by the Beijing Municipal Bureau of Economy and Information Technology [2]

北京莱伯泰科仪器股份有限公司 关于公司国家级专精特新"小巨人" 复核通过的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 基本情况 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2022 年被认定为 第四批国家级专精特新"小巨人"企业称号，有效期三年。 证券代码：688056 证券简称：莱伯泰科 公告编号：2025-038 1 三、 风险提示 公司本次通过国家级专精特新"小巨人"复核，不会对公司当期经营业绩产生 重大影响，敬请广大投资者谨慎投资，注意投资风险。 四、 备查文件 《北京市经济和信息化局关于北京市第七批专精特新"小巨人"企业和 2025 年专精特新"小巨人"复核通过企业名单进行公示的通知》 特此公告。 北京莱伯泰科仪器股份有限公司董事会 根据北京市经济和信息化局近日发布的《关于北京市第七批专精特新"小巨 人"企业和 2025 年专精特新"小巨人"复核通过企业名单进行公示的通知》，公司 已通过复核并继续被授予国家级专精特新"小巨人"企业称号，有效期三年。 二、 对公司的影响 国家级专 ...

Core Viewpoint - The company, 莱伯泰科, has successfully passed the national re-evaluation and continues to hold the title of "National Specialized and Innovative 'Little Giant' Enterprise" for another three years, reflecting government recognition of its innovation capabilities and market competitiveness [1] Group 1 - The company was recognized as a "Little Giant" enterprise in 2022, with the title valid for three years [1] - The recent announcement from the Beijing Economic and Information Technology Bureau confirms the company's re-evaluation and continued recognition [1] - This recognition enhances the company's visibility and market competitiveness, positively impacting its future development [1] Group 2 - The company aims to leverage this recognition to focus on its core business and innovation-driven development [1] - There is an emphasis on team building and market expansion to enhance core competitiveness and industry influence [1] - The goal is to become a leading and globally influential manufacturer in the instrumentation and meter industry [1]

Core Viewpoint - The company, Leibotech (688056.SH), has successfully passed the re-evaluation for the national-level "Specialized, Refined, Characteristic, and Innovative" small giant enterprise title, which is valid for three years, reflecting government recognition of its innovation capabilities and market competitiveness [1] Group 1: Company Recognition - The company was initially recognized as a national-level "Specialized, Refined, Characteristic, and Innovative" small giant enterprise in 2022, with a validity period of three years [1] - The recent announcement from the Beijing Municipal Bureau of Economy and Information Technology confirms the company's continued status as a national-level small giant enterprise [1] Group 2: Impact on Future Development - The successful re-evaluation enhances the company's visibility and market competitiveness, which is expected to have a positive impact on its future development [1] - The company aims to leverage this recognition to focus on its core business, emphasizing innovation and research and development as key drivers of growth [1] - The company plans to continue enhancing its core competitiveness and industry influence, striving to become a leading and globally influential manufacturer in the instrumentation sector [1]

Investment Rating - The report adjusts the investment rating to "Recommended" for the company, indicating an expected outperformance of 10%-20% relative to the benchmark index over the next six months [9][20]. Core Insights - The company reported a 23% year-on-year growth in non-recurring net profit for Q3, indicating a potential for new product launches to drive future growth [2][9]. - Despite a decline in revenue for the first three quarters of 2025, the company achieved a slight increase in net profit for Q3, suggesting an improving trend in profitability [2][9]. - The company’s core product received authoritative recognition, and new products are being launched, which are expected to contribute to future growth [9]. - The company has successfully expanded its overseas business, with foreign revenue increasing by 14.76% year-on-year, now accounting for 20.24% of total revenue [9]. Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 285 million yuan, a decrease of 8.43% year-on-year, and a net profit of 33 million yuan, down 7.26% year-on-year [2]. - The Q3 revenue was 93 million yuan, down 4.22% year-on-year, while the net profit for Q3 was 11 million yuan, up 1.76% year-on-year [2]. - The company’s gross margin for the first three quarters of 2025 was 45.80%, an increase of 0.94 percentage points year-on-year [9]. Future Projections - The company is expected to see net profits of 43 million yuan, 54 million yuan, and 66 million yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 10.8%, 24.8%, and 21.6% [9]. - The target price for the company is set at 40.1 yuan, reflecting a 13% upside from the current price of 35.48 yuan [4][9].

Group 1 - China Pacific Insurance's subsidiary, China Pacific Life, reported a cumulative premium income of 241.32 billion yuan for the first ten months, a year-on-year increase of 9.9% [1] - China Pacific Property Insurance, another subsidiary, achieved a cumulative premium income of 173.57 billion yuan, with a year-on-year growth of 0.4% [1] - Nocera Biopharma reported a net loss of 64.41 million yuan for the first three quarters, despite a revenue increase of 59.85% to 1.115 billion yuan [1] Group 2 - Founder Securities received approval from the China Securities Regulatory Commission to issue short-term corporate bonds not exceeding 5 billion yuan [1] - Haicheng Bonda's director plans to reduce his stake by up to 0.97%, equating to 198,400 shares [1] - Yuyuan Group intends to repurchase shares worth between 200 million and 300 million yuan, with a maximum price of 8.60 yuan per share [1] Group 3 - Huaren Shuanghe's subsidiary passed the GMP compliance inspection for a specific diabetes medication [4] - Lichong Group received project notifications from three international automotive manufacturers, with expected sales amounting to approximately 1.135 billion yuan [6] - Deyang Co. is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its global strategy [7] Group 4 - Longxin General announced the transfer of its entire stake in a subsidiary for 105.6 million yuan, and also plans to divest another stake for 1 yuan due to poor performance [16] - Kangda New Materials decided to terminate the acquisition of a semiconductor company due to unsatisfactory due diligence progress [17] - Lu'an Environmental reported a 3.28% year-on-year increase in coal sales for October, totaling 3.78 million tons [18] Group 5 - Shanghai Port Group plans to invest 2 billion yuan to establish a new holding company with several state-owned enterprises [20] - Borui Pharmaceutical's new drug for obesity treatment has received clinical trial approval [23] - Silver Dragon Co. has completed the registration of a new energy industry fund focusing on high-growth potential projects [24] Group 6 - Hengrui Medicine received approval for a clinical trial of a prostate cancer drug [11] - Baiji Shenzhou reported a net profit of 1.139 billion yuan for the first three quarters, marking a turnaround from losses [36] - Huasheng Pharmaceutical's special medical food product has received registration certification [60]

Market Overview - The Shanghai Composite Index closed at 4017.94 points, above the five-day moving average, with an increase of 0.44% [1] - The total trading volume of A-shares reached 12,733.37 million yuan [1] Stocks Performance - A total of 1,085 A-shares have surpassed the five-day moving average, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Tianhong Lithium Battery (17.41%) - Baiwei Storage (11.81%) - Derui Lithium Battery (8.69%) [1] Detailed Stock Data - The following table summarizes the performance of selected stocks that broke the five-day moving average: | Stock Code | Stock Name | Daily Change (%) | Turnover Rate (%) | Five-Day MA (yuan) | Latest Price (yuan) | Deviation Rate (%) | |------------|----------------|------------------|--------------------|---------------------|---------------------|---------------------| | 920252 | Tianhong Lithium| 26.37 | 28.72 | 31.75 | 37.28 | 17.41 | | 688525 | Baiwei Storage | 15.92 | 10.86 | 130.71 | 146.14 | 11.81 | | 920523 | Derui Lithium | 14.66 | 12.36 | 30.80 | 33.48 | 8.69 | | 301162 | Guoneng Rixin | 10.76 | 4.41 | 58.82 | 63.60 | 8.13 | | 300584 | Haichen Pharma | 12.07 | 15.81 | 56.42 | 60.80 | 7.77 | | 300432 | Fulian Precision | 13.30 | 7.30 | 19.13 | 20.61 | 7.73 | | 603966 | Falan Technology | 10.03 | 10.44 | 11.22 | 12.07 | 7.56 | | 002208 | Hefei Urban Construction | 10.01 | 14.27 | 11.98 | 12.86 | 7.33 | | 000633 | Alloy Investment | 10.00 | 3.43 | 6.97 | 7.48 | 7.32 | | 301358 | Hunan Yunan | 11.64 | 5.91 | 82.36 | 88.27 | 7.18 | | 002227 | Aotexun | 9.99 | 6.24 | 13.88 | 14.87 | 7.12 | | 001266 | Hongying Intelligent | 10.01 | 10.99 | 30.78 | 32.97 | 7.12 | | 003022 | Lianhong New Technology | 10.00 | 1.46 | 20.88 | 22.32 | 6.91 | | 301379 | Tianshan Electronics | 9.65 | 11.89 | 28.21 | 30.10 | 6.70 | | 603188 | Yabang Shares | 10.02 | 8.83 | 5.25 | 5.60 | 6.67 | | 600686 | Jinlong Automobile | 9.08 | 6.54 | 15.43 | 16.46 | 6.66 | | 002108 | Cangzhou Ming | 10.04 | 8.50 | 4.93 | 5.26 | 6.61 [1][2]

证券代码：688056 证券简称：莱伯泰科 公告编号：2025-037 重要内容提示： 投资者可于 2025 年 11 月 12 日 （星期三） 至 11 月 18 日 （星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqtzb@labtechgroup.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京莱伯泰科仪器股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 19 日（星 期三）16:00-17:00 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行 交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 会议召开时间：2025 年 11 月 19 日（星期三）16:00-17: ...

Job Opportunities - Various sales positions are available in the instrumentation and testing industry, including roles at Agilent, LanYou Technology, and others, with salary ranges from 5k to 22k per month depending on the position and experience [3][5][8][10][12][14][16][18][20][22]. - Requirements for these positions typically include a bachelor's degree in relevant fields such as chemistry, biology, or engineering, along with several years of sales experience in related industries [6][10][12][18][20][22]. Sales Engineer Roles - Sales Engineer positions are offered by companies like Jingzhi Times and Huaxia Puchuang, with salaries ranging from 7k to 15k per month [10][20]. - Candidates are expected to have a strong background in science or engineering, excellent communication skills, and the ability to work independently while managing customer relationships [10][12][20]. R&D Positions - R&D roles are available at companies such as Jingtai Technology and Laibotai Technology, with salaries ranging from 9k to 45k per month [24][27][29][33]. - These positions require advanced degrees in fields like analytical chemistry or mechanical engineering, along with specific technical skills related to instrumentation and software development [25][27][29][33]. Application and Technical Support Roles - Positions such as Application Technology Engineer at Puyue Technology focus on providing technical support and developing application methods for laboratory instruments, with salaries around 8k to 13k per month [40]. - Candidates should have a strong understanding of analytical instruments and the ability to communicate effectively with clients and experts [40].